These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 37936450)
1. Dual Role of Pregnane X Receptor in Nonalcoholic Fatty Liver Disease. Xu Y; An Z; Wang S; Ni Y; Zhou M; Feng Q; Gou X; Xu M; Qi Y Curr Mol Pharmacol; 2023 Oct; ():. PubMed ID: 37936450 [TBL] [Abstract][Full Text] [Related]
5. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease. Li X; Wang Z; Klaunig JE Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929 [TBL] [Abstract][Full Text] [Related]
6. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690 [TBL] [Abstract][Full Text] [Related]
7. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M Gene; 2020 Jun; 742():144549. PubMed ID: 32184169 [TBL] [Abstract][Full Text] [Related]
8. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Brown E; Hydes T; Hamid A; Cuthbertson DJ Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271 [TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Ota T Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745 [TBL] [Abstract][Full Text] [Related]
10. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185 [TBL] [Abstract][Full Text] [Related]
11. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). Roeb E Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943 [TBL] [Abstract][Full Text] [Related]
12. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
13. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590 [TBL] [Abstract][Full Text] [Related]
14. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986 [TBL] [Abstract][Full Text] [Related]
15. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310 [TBL] [Abstract][Full Text] [Related]
16. Polychlorinated biphenyls altered gut microbiome in CAR and PXR knockout mice exhibiting toxicant-associated steatohepatitis. Wahlang B; Alexander NC; Li X; Rouchka EC; Kirpich IA; Cave MC Toxicol Rep; 2021; 8():536-547. PubMed ID: 33777700 [TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908 [TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease - current status and future directions. Demir M; Lang S; Steffen HM J Dig Dis; 2015 Oct; 16(10):541-57. PubMed ID: 26406351 [TBL] [Abstract][Full Text] [Related]
19. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Sugimoto K; Inui H; Fukusato T World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263 [TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]